Nasal polyps are benign growth or lesions arising from the mucosa of the nasal sinuses. Nasal polyps may occur in association with asthma, sinus infections, allergic infections, aspirin sensitivity, and cystic fibrosis. Pharmacological therapies such as corticosteroids, antibiotics, leukotriene inhibitors and surgical treatment options are widely adopted for treating patients with nasal polyps.
Adroit Market Research study on the global market for nasal polyps treatment offers a holistic view of the industry from 2020 to 2028 as forecast period, including factors such as market drivers, limitations, opportunities, threats and regulatory overview. The market has been analyzed from 2018 to 2028, with a base year estimate of 2019 and a projection from 2020 to 2028. The report covers the current status and potential characteristics of the market at both the global and the country level. Moreover, the report also assesses market competition with Porter's analysis of five strengths and places leading players on the basis of their product range, regional presence, strategic initiatives and overall sales. Prominent players in the global nasal polyps treatment market have been analyzed in depth.
The need for the treatment of nasal polyps is rising immensely owing to high prevalence of inflammatory respiratory disorders such as chronic rhinosinusitis with nasal polyps. It is estimated that, approximately four percent of the population suffers from chronic rhinosinusitis with nasal polyps which increases the demand for effective treatment. However, high cost of treatment, stigma associated with steroid therapies, post-surgical complication and recurrence of the disease are some of the major factors hampering the growth of the nasal polyps treatment market.
Hospitals, ambulatory surgical centers and specialty clinics carry out surgical procedures for the treatment of nasal polyps including polypectomy and functional endoscopic sinus surgery (FESS). There is rapid shift from operating rooms to ambulatory surgical centers for sinus surgeries because of minimal duration of stay, patient satisfaction, lower infection rates and greater efficiency.
North America dominated the nasal polyps treatment market owing to increase in prevalence of inflammatory respiratory disorders. According to CDC, approximately 28.9 million adults in the U.S. were diagnosed with sinusitis in 2018. Asia Pacific is expected to witness a lucrative growth during the forecast period owing to presence of large geriatric population suffering with respiratory disorders. Moreover, the growing demand for corticosteroids in developing regions is expected to fuel market growth for nasal polyps treatment in the next few years.
- key players operating in the global nasal polyps treatment market include Intersect ENT, Inc., GlaxoSmithKline plc, OptiNose US, Inc., Sanofi, Merck & Co, Inc., Pfizer, Novartis AG, F. Hoffmann-La Roche Ltd., and Regeneron Pharmaceuticals, Inc.
Key Segments of the Global Nasal Polyps Treatment Market
Treatment Type Overview, 2018-2028 (USD Million)
- Pharmacological Therapies
- Antibiotics
- Corticosteroids
- Leukotriene Inhibitors
- Others
- Surgery
- Polypectomy
- Functional Endoscopic Sinus Surgery (FESS)
End-user Overview, 2018-2028 (USD Million)
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
Regional Overview, 2018-2028 (USD Million)
- North America
- U.S.
- Canada
- Europe
- Germany
- United Kingdom
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa